CORRIGENDUM


Corrigendum to: Clarithromycin versus Amoxicillin alone or with Clavulanate in Acute Maxillary Sinusitis: A Meta-analysis of Clinical Trials



Daryl J. Hoban1, Jos Nauta2, *
1 Department of Medical Microbiology and Infectious Disease, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
2 Innovation & Development, Established Pharmaceuticals, Abbott Healthcare Products B.V., Weesp, The Netherlands


© 2021 Hoban & Nauta.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at Innovation & Development, Established Pharmaceuticals, Abbott Healthcare Products B.V., C.J. van Houtenlaan 36, 1381 CP Weesp, The Netherlands; Tel: +31 (0) 294 47 7360; E-mail: jos.nauta@abbott.com




A typographical error appeared in Section 3.5 of the article titled “Clarithromycin versus Amoxicillin alone or with Clavulanate in Acute Maxillary Sinusitis: A Meta-analysis of Clinical Trials”, published in “The Open Infectious Diseases Journal”, 2021 Apr 16; 13(1). [1].

Details of the error and a correction are provided here.

We regret the error and apologize to readers.

The original article can be found online at: https:// openinfectiousdiseasesjournal.com/VOLUME/13/PAGE/1/

Original:

Bacteriologic cure rates were reported for five of the six studies (Table 5). Cure rates varied between 87.9% and 94.6% with clarithromycin...

Corrected:

Bacteriologic cure rates were reported for four of the six studies (Table 5). Cure rates varied between 87.1% and 94.6% with clarithromycin….

REFERENCE

[1] Hoban DJ, Nauta J. Clarithromycin versus Amoxicillin alone or with Clavulanate in Acute Maxillary Sinusitis: A Meta-analysis of Clinical Trials. Open Infect Dis J 2021; 13(1)